02893nas a2200265 4500000000100000008004100001260003700042653002400079653005700103100001500160700001500175700001400190700001700204700001400221700001100235700001100246700001400257700001300271245015400284856009900438300001300537490000700550520205600557022001402613 2022 d bPublic Library of Science (PLoS)10aInfectious Diseases10aPublic Health, Environmental and Occupational Health1 aTitaley CR1 aWorrell CM1 aAriawan I1 aTaihuttu YMJ1 ade Lima F1 aNaz SF1 aQue BJ1 aKrentel A1 aStolk WA00aAssessment of factors related to individuals who were never treated during mass drug administration for lymphatic filariasis in Ambon City, Indonesia uhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0010900&type=printable ae00109000 v163 a

Background One challenge to achieving Lymphatic filariasis (LF) elimination is the persistent coverage-compliance gap during annual mass drug administration (MDA) and the risk of ongoing transmission among never treated individuals. Our analysis examined factors associated with individuals who were never treated during MDA.

Methods Data were derived from two cross-sectional surveys conducted in Waihaong and Air Salobar Health Center in 2018 and 2019. We analyzed information from 1915 respondents aged 18+ years. The study outcome was individuals who self-reported never treatment during any round of MDA. All potential predictors were grouped into socio-demographic, health system, therapy and individual factors. Logistic regression analyses were used to examine factors associated with never treatment in any year of MDA. Results Nearly half (41%) of respondents self-reported they were never treated during any round of MDA. Factors associated with increased odds of never treatment were respondents working in formal sectors (aOR = 1.75, p = 0.040), living in the catchment area of Waihaong Health Center (aOR = 2.33, p = 0.029), and those perceiving the possibility of adverse events after swallowing LF drugs (aOR = 2.86, p<0.001). Respondents reporting difficulty swallowing all the drugs (aOR = 3.12, p<0.001) and having difficulties remembering the time to swallow the drugs (aOR = 1.53, p = 0.049) also had an increased odds of never treatment. The highest odds of never treatment were associated with respondents reporting almost none of their family members took LF drugs (aOR = 3.93, p<0.001). Respondents confident that they knew how to swallow LF drugs had a reduced odds (aOR = 0.26, p<0.001) of never treatment. Conclusions Efforts to reassure community members about adverse events, specific instructions on how to take LF drugs, and improving awareness that MDA participation is part of one’s contribution to promoting community health are essential drivers for uptake with LF drugs during MDA.

 a1935-2735